The group buys out its partner Genetx, but inconsistent data spook investors.
GSK takes on arthritis and Roche aims for convenience, while Pfizer is set to report infant pneumococcal vaccine data.
A couple of small M&A deals this week shows more developers capitulating to the new reality.
All-comer Serd studies in pretreated breast cancer look doomed, so why do Astra and Lilly persist? And why isn’t Radius seizing its advantage?
Giredestrant fails, but the group hopes for better luck in earlier therapy lines.
Amcenestrant flunks the long-delayed Ameera-3 trial in ER-positive Her2-negative breast cancer, so how much blame can be put on poor study design?
The company’s new osteoporosis formulation is not a patch on the original.
Trial design comes into focus as late-stage readouts loom for Sanofi, Roche and Astrazeneca.